Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label vatiquinone rollover study in Friedreich ataxia
2024-516505-23-00Phase 3Authorised
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of vatiquinone in Friedreich ataxia (FA), sponsored by PTC Therapeutics, Inc. Primary endpoint: Safety and tolerability. Planned start Mar 2023; status: authorised.
02
Drugs
vatiquinone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2024-516505-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516505-23-00.